An IHC study on resected BC tissues showed a gradual elevation in IGFBP-2 expression from atypical hyperplasia through to carcinoma in situ and invasive carcinoma [35] and a TMA analysis of more than 4,000 primary invasive breast tumours indicated that an adverse survival outcome is correlated with IGFBP-2 expression in ERα negative tumours [41]. The gene discussed is IGFBP2; the disease is cancer.